Since 1960, there have been six clinical trials of Coley Fluid. In these trials, Coley Fluid was tested in patients who were receiving or had previously been treated with chemotherapy and/or radiation therapy. In contrast, at MBVax Bioscience we will study Coley Fluid as a stand alone therapy, that is without the use of chemotherapy or radiation therapy which can suppress the immune system."

1962 – Johnston Trial – various cancers.

• 137 cancer patients, all of whom were considered terminal, received 5,244 intravenous doses, 917 intra-muscular doses, and 41 intra-tumoural doses of Coley Fluid. In one series of 93 patients with progressive disease that no longer responded to chemotherapy or radiation therapy, 43 patients showed no improvement, 20 showed subjective improvements such as weight gain and decrease in pain, and 33 showed measurable improvements including long-term survival and one apparent cure.

1981/83 – Kempin Trial – non-Hodgkin’s lymphoma.

• Advanced nodular non-Hodgkin’s lymphoma patients were randomized to receive Coley Fluid or no Coley Fluid prior to chemotherapy.

1988 – Axelrod Trial – various cancers.

• 13 patients with “metastatic or locally advanced non-curable disease” received 130 intravenous doses of Coley Fluid. One patient had a partial response and 4 patients had stable disease at the end of 8 weeks treatment

1991 – Kolmel Trial – malignant melanoma.

• This study focused on 15 patients with advanced melanoma; most had skin tumours, some had metastases into other organs of the body. The treatment consisted of 12 or more weekly intravenous injections of Coley Fluid. The treatment resulted in three total and lasting remissions. One patient achieved a period of stability before the disease progressed. All three patients with complete regressions were disease free at 32, 21, and 15 months. One of the authors of the article, Dr. E. Göhring, used this therapy prior to the study and achieved a complete regression of stage IV melanoma with lung and liver metastases.

1991 – Tang Trial – liver cancer.

• 38 patients with operable liver cancer were randomized to receive, in addition to chemotherapy, Coley Fluid or no Coley Fluid; and 48 patients with inoperable liver cancer were randomized to receive, in addition to chemotherapy and radiation, Coley Fluid or no Coley Fluid. In series 1, the 1- and 2-year survival rates of the Coley Fluid group and the control group were 75% vs 58%, and 45% vs 39%. In series 2, the 1- 2- and 3-year survival rates were 59%, 41% and 41% for the Coley Fluid group and 39%, 25% and 20% for the control group.

1993 – Havas Trial – various cancers.

• 11 cancer patients with refractory malignancies received Coley Fluid as a single agent. One patient had a partial response, four patients had temporary stabilization, and one patient with AIDS and Kaposi’s sarcoma experienced a dramatic improvement in performance status and disease stabilization.